Effect of switching from high dose fluticasone propionate (FP) to FP/salmeterol (FSC) on airway inflammation in asthma
S. J. Wilson, H. M. Rigden, N. Jarjour, M. Laviolette, W. C. Moore, P. M. Dorinsky, S. W. Yancey, R. Djukanovic (Southampton, United Kingdom; Madison, Winston-Salem, Research Triangle Park, United States Of America; Quebec, Canada)
Source: Annual Congress 2004 - Advancements in pathobiology of respiratory diseases
Session: Advancements in pathobiology of respiratory diseases
Session type: Poster Discussion
Number: 398
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. J. Wilson, H. M. Rigden, N. Jarjour, M. Laviolette, W. C. Moore, P. M. Dorinsky, S. W. Yancey, R. Djukanovic (Southampton, United Kingdom; Madison, Winston-Salem, Research Triangle Park, United States Of America; Quebec, Canada). Effect of switching from high dose fluticasone propionate (FP) to FP/salmeterol (FSC) on airway inflammation in asthma. Eur Respir J 2004; 24: Suppl. 48, 398
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Control of airway inflammation is maintained in asthma patients following a 60% reduction in ICS dose with fluticasone propionate/salmeterol (FSC) compared with higher dose fluticasone propionate (FP) alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004
Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
In vivo dose response relation of inhaled fluticasone propionate (FP), adults with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
Late Breaking Abstract - Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects. Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019
Variability in asthma and treatment efficacy as determined by weekly response rates with fluticasone propionate/salmeterol 100/50mcg (FSC) compared with montelukast 10mg (MON) Source: Eur Respir J 2003; 22: Suppl. 45, 259s Year: 2003
Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Higher cellular retention and activity after pulse exposure by budesonide (BUD) than fluticasone propionate (FP) and mometasone furoate (MF) Source: Eur Respir J 2001; 18: Suppl. 33, 158s Year: 2001
Effect of addition of salmeterol vs doubling the dose of fluticasone propionate on specific airway resistance in children with asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008
"Stepping down" in mild-to-moderate asthmatic children, being well controlled while receiving low doses of inhaled corticosteroids (ICS): nedocromil sodium (NS) vs. fluticasone propionate (FP) 100 mcg/day given either twice Source: Eur Respir J 2006; 28: Suppl. 50, 713s Year: 2006
Effect of combination fluticasone propionate and salmeterol diskhaler in treatment of moderate to severe asthma: comparison of initial high dose, constant medium dose and placebo Source: Eur Respir J 2001; 18: Suppl. 33, 123s Year: 2001
Comparison of salmeterol/fluticasone propionate (sal/fp) combination versus monotherapy with fluticasone propionate (fp) in patients with mild to moderate asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009
Effect of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) on risk of severe exacerbations in asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
The combination salmeterol (S) + fluticasone propionate (F) in mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001
Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS) Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
Fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), demonstrates once-daily (OD) efficacy in asthma when dosed in the evening Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Sustained protection against activity-induced bronchospasm (AIB) during chronic treatment with the fluticasone propionate/salmeterol combination (FSC) Source: Eur Respir J 2002; 20: Suppl. 38, 308s Year: 2002
A comparison of salmeterol xinafoate (SX) plus fluticasone propionate (FP) and slow-release theophylline (Theo) plus FP in the treatment of stable chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 31s Year: 2006
Effect of fluticasone propionate (FP)/salmeterol 100/50mcg or FP 250mcg on small airway function Source: Eur Respir J 2003; 22: Suppl. 45, 260s Year: 2003